GLP-1 receptor agonists

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.

The first once-daily oral GLP-1 medication could be on shelves by this time next year, making the weight-loss drug easier to take and potentially cheaper. In the race to be the first, Novo Nordisk has scored a huge win, while Pfizer has failed again.

GLP-1 drugs have reportedly changed people's relationship with more than just food, but it's been largely anecdotal. Now, there's evidence that Ozempic blocks alcohol cravings – which could be a game-changer for people who want to cut back on booze.

There's a growing body of evidence that gold nanoparticles can trigger significant weight loss that targets fat, without affecting muscles, plus heal organs and improve blood-glucose levels. A new study makes a strong case for the first-ever human trial.

Scientists remain puzzled as to why some people taking popular weight loss and diabetes medications like Ozempic and Wegovy are losing their vision suddenly, highlighting that there's still so much we don't know about this life-changing class of drugs.

If you're one of the 13% of US adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly melts away, so too does muscle. And, so far, there's not a lot you can do about it. But one new discovery may change this.

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs; that number falls significantly when they learn the weight might come back when the meds are stopped. It’s something that has medical professionals concerned.

Studies presented at a recent American Heart Association conference have confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, and how lifestyle interventions for weight loss affect heart biomarkers in diabetics.

Game-changing GLP-1 agonist drugs are a step closer to being available in oral pill form, with AstraZeneca revealing "encouraging data" from the Phase I safety and tolerability trial of its once-daily obesity and diabetes drug AZD5004.

Rapid weight loss can cause a greater loss of muscle mass than losing weight slowly. The popularity of newer weight-loss drugs that shed pounds quickly has raised concerns among researchers about how this will affect the health of our muscles.

The race is on to deliver the first once-a-day weight-loss pill that would be both cheaper and less invasive than the current injectable drugs, with strong results from Terns following those from competitors Eli Lilly, Pfizer, Roche and Structure.

People living with diabetes might have a new hope. Scientists have tested a new drug therapy in diabetic mice, and found that it boosted insulin-producing cells by 700% over three months, effectively reversing their disease.